Inventiva To Present At The Jefferies 2017 Global Healthcare Conference

Published: Jun 07, 2017

DAIX, France--()--Regulatory News:

Inventiva (Paris:IVA) (Euronext Paris - FR0013233012 – IVA), a biopharmaceutical company developing innovative therapies, particularly to treat fibrosis, announced today that Frederic Cren, Chief Executive Officer, will present a corporate overview at the Jefferies 2017 Global Healthcare Conference, being held June 6-9 at the Grand Hyatt Hotel in New York City.

Presentation Details - Jefferies Global Healthcare Conference

Date: June 9
Time: 10:30am Eastern Time

ballroom 4

About Inventiva:

Inventiva is a biopharmaceutical company specialized in the development of drugs interacting with nuclear receptors, transcription factors and epigenetic modulators. Inventiva’s research engine opens up novel breakthrough therapies against fibrotic diseases, cancers and orphan diseases with substantial unmet medical needs.

IVA337, its lead product, is an anti-fibrotic treatment with a strong action mechanism permitting the activation of all three alpha, gamma and delta PPARs (peroxisome proliferator-activated receptors), which play key roles in controlling the fibrotic process. Its anti-fibrotic action targets two initial indications with substantial unmet medical need: NASH, a severe and increasingly prevalent liver disease already affecting over 30 million people in the United States, and systemic sclerosis, a disease with a very high mortality rate and for which there is no approved treatment to date.

Inventiva is also developing in parallel, a second clinical product, IVA336, which is a treatment for three different forms of mucopolysaccharidosis: MPS I or Hurler-Scheie syndrome, MPS II or Hunter syndrome and MPS VI also known as Maroteaux-Lamy syndrome. Inventiva has a preclinical stage oncology portfolio.

Inventiva benefits from partnerships with world-leading research entities such as the Institut Curie. Two strategic commercial partnerships, one of which is at clinical stage, have also been developed with AbbVie and Boehringer Ingelheim, making Inventiva eligible for preclinical, clinical, regulatory and commercial milestone payments, in addition to royalties on the products resulting from the partnerships.

Inventiva employs over 100 highly qualified employees and owns state-of-the-art R&D facilities near Dijon, acquired from the international pharmaceutical group Abbott. The Company owns, a proprietary chemical library of over 240,000 molecules as well as integrated biology, chemistry, ADME and pharmacology platforms.

Important Notice:

Some of the statements contained in this document are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management's beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance or future events to differ materially from those expressed or implied in such statements.

Please refer to the « Document de Base » filed with the Autorité des Marchés Financiers on July 8, 2016 under n° l.16-066, and its update submitted on January 12, 2017 under n° D.16-0535-A01 for additional information in relation to such factors, risks and uncertainties.

Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above. Consequently Inventiva accepts no liability for any consequences arising from the use of any of the above statements.

Frédéric Cren
Chief Executive Officer
+33 (0)3 80 44 75 00
Julien Perez / Mathilde Bohin
Investor Relations
+33 (0)1 44 71 98 52
Nicolas Merigeau / Arthur Rouillé
Media Relations
+33 (0)1 44 71 94 98
LifeSci Advisors
Chris Maggos
Investor Relations
+41 79 367 6254

Back to news